GlobalData on MSN9h
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedemaThe HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of ...
Zacks.com on MSN9h
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema CandidateIntellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback